Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Oct 25, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Caris Life Sciences and Threshold Pharmaceuticals announced today that they have partnered to develop a tissue-based assay to predict how pancreatic cancer patients will respond to Threshold’s investigational drug evofosfamide.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

  2. Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

  3. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  4. JP Morgan Downgrades Illumina to Neutral on Grail Deal

  5. Promega to Develop MSI Assay as CDx for Incyte Endometrial Cancer Drug

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.